At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see if combining radiation therapy and immunotherapy is safe and works well for treating advanced adrenocortical cancer. The people in this study have adrenocortical cancer that spread to other parts of the body, including the liver.
-
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
-
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
-
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
-
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
- A Phase 1 Study of FT825 CAR T-Cell Therapy With or Without Cetuximab in People With Solid Tumors
Full Title A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
Purpose
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth.
FT825 is a cellular therapy made from cells collected from a healthy donor. The donor cells are genetically modified (changed) to turn them into cells called induced pluripotent stem cells (iPSCs). iPSCs can be made to change into different cell types. In this study, iPSCs are used to make white blood cells called T cells. Some cancers can block T cells from attacking tumor cells.
Researchers will use genetically modified T cells to help them work against cancer cells. These modified T cells are called chimeric antigen receptor (CAR) T cells. Treatments made from them are called CAR T-cell therapies. They are a form of immunotherapy.
If you join this study, you will first get the chemotherapy drugs fludarabine and cyclophosphamide or bendamustine. These medicines help prepare your body for FT825. Some people whose cancer has an EGFR mutation will also receive cetuximab, a standard therapy for many cancers. The treatments are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have an advanced solid tumor that makes high levels of HER2. Examples include breast, non-small cell lung, gastroesophageal junction, stomach, gynecologic, and colorectal cancers.
- Have completed prior anti-cancer treatments at least 2 weeks before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older
Contact
For more information or to see if you can join this study, please call Dr. Roisin O’Cearbhaill’s office at 646-608-2091.
Protocol
24-297Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06241456ClinicalTrials.gov
-
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
-
This study is comparing two treatment regimens for advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma that has metastasized (spread). They have not yet had treatment for advanced disease.
-
Researchers in this study want to compare sentinel lymph node biopsy surgery with standard neck dissection as part of the treatment for people with early-stage oral cavity (mouth) cancer. Sentinel lymph node biopsy is a procedure that removes a smaller number of lymph nodes from the neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard elective neck dissection removes many of the lymph nodes in the neck but may reduce shoulder mobility and strength.
-
Researchers want to learn if combining lasofoxifene and abemaciclib works well in people with advanced breast cancer. This treatment will be compared to the usual breast cancer treatment with fulvestrant and abemaciclib. The people in this study have breast cancer that is fueled by estrogen and does not have the HER2 protein. They also have a mutation (change or variant) in the ESR1 gene. Lasofoxifene targets the ESR1 gene mutation.